Rare tumours

Overview

Defining the activity of two targeted agents in multiple rare tumour settings and preliminarily seek markers of disease and drug sensitivities.

Study of sunitinib or temsirolimus in patients with very rare tumours

Principal investigator: Janet Dancey, Queen’s University

Co-applicants: Dongsheng Tu, Hal Hirte, Ming Tsao, John McPherson

Primary objective: To define the activity of two targeted agents in multiple rare tumour settings and preliminarily seek markers of disease and drug sensitivity/resistance.

Goals:

• To evaluate a novel clinical trial design to efficiently screen for anti-tumour activity of two targeted agents in rare tumour settings;
• To analyze tumour and blood samples to identify preliminary markers of disease and drug susceptibility in archival and fresh tumour samples from patients in rare tumour cohorts.